Prevention of Acute Kidney Injury in Patients With NSTEMI

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography. Approximately 220 patients with CKD and acute NSTEMI, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of NSTEMI).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pharming Technologies B.V.
• Treatments: Complement C1 Inhibitor Protein

Criteria

Inclusion Criteria:

1. Informed Consent as documented by a signature and date of the patient

2. Age 18-85 years

3. Acute NSTEMI as anticipated to be type 1 (expert opinion by the cardiologist before coronary angiography) and scheduled for urgent coronary angiography

4. Documented kidney disease existing for ≥3 months OR Two estimated glomerular filtration rate (eGFR) measurements of <60ml/min/1.73m2 as calculated by the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) study equation and at least 6 hours apart OR eGFR of <50 mL/min//1.73m2 as calculated by using the CKD-EPI study equation at presentation

5. At least one of the following risk factors for AKI: diabetes mellitus, age >60 years, established cardiovascular disease, heart failure with reduced ejection fraction, anemia

Exclusion Criteria:

1. Contraindications to the class of drugs under study (C1 esterase inhibitors), e.g. known hypersensitivity or allergy to class of drugs or the IMP

2. History or suspicion of allergy to rabbits

3. Women who are pregnant or breast feeding

4. ST elevation myocardial infarction or unstable angina

5. Cardiogenic shock requiring mechanical support

6. Non-cardiac comorbidity with expected survival <6 months

7. Acute urinary tract infection (e.g. cystitis, pyelonephritis).

8. Liver cirrhosis (any Child-Pugh score)

9. Dialysis or eGFR <20 and >59mL/min/1.73 m2 at baseline (d0)

10. Incapacity or inability to provide informed consent

11. Participation in another study with investigational drug within 30 days preceding, and during the present study

12. Previous enrolment into the current study